Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
The Pacira Pharmaceuticals price is unchanged compared to yesterday.
With 7 Buy predictions and not the single Sell prediction the community is currently very high on Pacira Pharmaceuticals.
With a target price of 27 € there is a positive potential of 37.76% for Pacira Pharmaceuticals compared to the current price of 19.6 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | 6.806% | 15.254% | -0.971% | -5.556% | -43.956% | -65.424% |
| Rockwell Medical Inc. | -0.310% | -1.742% | -9.453% | -51.029% | 12.565% | -34.353% | -93.707% |
| Twist Bioscience Corp | 3.080% | -6.052% | -5.141% | 6.536% | 40.467% | 147.532% | -66.564% |
| Savara Inc. | 0.900% | -2.609% | -2.609% | 88.235% | -15.472% | 121.782% | 101.802% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat